Fig. 17From: Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysisSubgroup analysis of diarrhea in accordance with therapy setting (L vs. T)Back to article page